Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860416 · ClinicalTrials.gov registry record
Additional Post Hoc Analysis and Clinical Data Collection
A clinical trial, sponsored by ElMindA.
- Completed
- Registry status
- 55
- Enrollment target
NCT02860416: Completed study, sponsored by ElMindA.
NCT02860416 is a clinical trial that has completed, run by ElMindA. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02860416 has completed, sponsored by ElMindA.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to collect additional Investigational cognitive tasks and additional clinical data for subjects tested with ElMindA's Brain Network Activation (BNA™).
Primary Outcome
The study is designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical assessments and BNA scores. The results are primarily intended for scientific inquiry and engineering development purposes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-10 |
What the finished NCT02860416 record still lists
NCT02860416 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02860416 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02860416 about?
NCT02860416 is a clinical study titled "Additional Post Hoc Analysis and Clinical Data Collection". The purpose of this study is to collect additional Investigational cognitive tasks and additional clinical data for subjects tested with ElMindA's Brain Network Activation (BNA™).
What is the current status of trial NCT02860416?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2016-07. Estimated completion is 2018-10.
Who is sponsoring clinical trial NCT02860416?
This trial is sponsored by ElMindA, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia